ELCC News: A new genetic signature helps identify risk of relapse in patients with completely resected early NSCLC
The majority of the genes in the classifier are either immune-derived or immunomodulatory
ELCC 2012: News
ELCC News: A new potential biomarker of response in lung cancer chemoprevention studies
miR-34c is a transcriptional target of p53 and potentially new quantitative biomarker of response
ELCC News: Biomarker analysis of the TORCH study shows that patients with advanced NSCLC should receive first-line erlotinib only if their tumour harbours EGFR mutations
Patients with unknown or negative EGFR mutation status should be treated with the standard chemotherapy first
ELCC News: Validation of the prognostic role of tumour lymphocytic infiltration on overall survival in patients with resectable NSCLC
LACE-Bio team confirms intense lymphocytic infiltration as a favourable prognostic factor